<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02997553</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00799-42</org_study_id>
    <nct_id>NCT02997553</nct_id>
  </id_info>
  <brief_title>Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery</brief_title>
  <acronym>GASVERT</acronym>
  <official_title>Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine
      green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided
      sentinel lymph node biopsy in patients with cancers and subjected to surgery.

      The diagnostic performance and the tolerance of indocyanine green (ICG) to the radio-isotope
      (Techniciun99) in the detection of sentinel lymph nodes will be assess using an &quot;Optonuclear&quot;
      probe (EURORAD S.A.).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of indocyanine green guided sentinel lymph node biopsy</measure>
    <time_frame>1 day</time_frame>
    <description>The detection rate is defined by the number of patient who at least one sentinel node detected by fluorescence or isotope intra operatively.
Per-operative detection is defined by the identification of at least one sentinel lymph node in the lymphatic drainage area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of sentinel lymph node detected</measure>
    <time_frame>1 day</time_frame>
    <description>The total number of sentinel node detected will be assess by the two techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of false negative result</measure>
    <time_frame>1 day</time_frame>
    <description>False negative result is defined by number of patients with at least one hot metastatic sentinel lymph node without fluorescent metastatic sentinel lymph node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergic reactions</measure>
    <time_frame>8 days</time_frame>
    <description>Percentage of patients with allergic reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>1 day</time_frame>
    <description>Pain will be assessed by a numerical scale from 0 (no pain) to 10 (maximum pain)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">744</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Squamous Cell Carcinoma, Skin</condition>
  <condition>Cervix Cancer</condition>
  <condition>Endometrium Cancer</condition>
  <condition>Ovary Cancer</condition>
  <condition>Vulva Cancer</condition>
  <condition>Anus Cancer</condition>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient receive both injections of Technetium99 (standard care) and indocyanine green.
The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <other_name>Infracyanine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technetium99</intervention_name>
    <description>Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.
Lymphoscintigraphy is performed to identify the sentinel node</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <other_name>NANOCIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optonuclear probe</intervention_name>
    <description>The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years

          -  cancer histologically proved

          -  patient eligible for sentinel node detection

          -  first surgical treatment

          -  contraceptive methods for men and women of childbearing age

          -  signed informed consent form

          -  patient affiliated to the social security system

        Exclusion Criteria:

          -  neoadjuvant chemotherapy or hormone therapy

          -  adenopathy (s) clinically suspicious or positively cytopenic

          -  women who are pregnant or breast-feeding

          -  associated pathology that may prevent patient of receive indocyanine green

          -  ongoing participation in another clinical trial with an investigational drug

          -  patients deprived of liberty or under supervision

          -  impossibility to undergo medical follow-up of the trial for geographical, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARCHAL FREDERIC, MD, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN JEAN LOUIS</last_name>
    <phone>+ 33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES LAURINDA</last_name>
    <phone>+ 33 3 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marchal Frédéric, MD PU-PH</last_name>
      <phone>+ 33 3 83 59 84 51</phone>
      <email>f.marchal@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indocyanine green (ICG)</keyword>
  <keyword>Sentinel lymph node biopsy</keyword>
  <keyword>Technetium99</keyword>
  <keyword>Tumors</keyword>
  <keyword>Optonuclear probe</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

